Gene therapy for rare retinal disorder to cost $425,000 per eye

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited ...

Posted: Jan 4, 2018 8:16 AM
Updated: Jan 4, 2018 8:16 AM

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.

Spark Therapeutics Inc., the Philadelphia-based maker of voretigene neparvovec, announced Wednesday in a statement that it reached an agreement in principle with Harvard Pilgrim and affiliates of-Express Scripts to make the one-time treatment available to patients with a rare genetic defect that often leads to blindness.

Luxturna, a one-time treatment, corrects a genetic mutation that can lead to blindness

Spark Therapeutics set the price for the gene therapy at $425,000 per eye

The mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.

In some cases, the gene therapy will be available under an "outcomes-based rebate arrangement." The company also stated that its proposal to the Centers for Medicare and Medicaid Services, the government program that covers about 100 million Americans, would allow installment payments for the drug.

"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed," said Jennifer Luddy, a spokeswoman for Express Scripts.

At least one patient advocate disagrees.

"The new payment models announced today are merely a way to disguise a price that is simply too high," David Mitchell, president and founder of Patients For Affordable Drugs, said in a statement. "Spark Therapeutics is charging as much for Luxturna as they think they can get away with."

Spark Therapeutics CEO Jeff Marrazzo co-authored a recent blog post in the journal Health Affairs that said "the current payment system -- accustomed to ongoing treatment of chronic diseases -- creates significant challenges" for gene therapies and other treatments.

One-time-only treatments for rare genetic disorders are still unique, he noted.

The drug is intended for patients with retinal dystrophy due to a mutation of the RPE65 gene. This rare genetic defect causes severe visual impairment beginning in infancy and can eventually lead to blindness. The company believes the total "population in the US, Europe and select additional markets in the Americas and Asia/Pacific is up to approximately 6,000 individuals" who have the mutation targeted by Luxturna, explained Monique da Silva, a spokeswoman for Spark Therapeutics.

The drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.

Luxturna is only the third gene therapy approved for use in the United States; two others were also approved in 2017. This is the first to correct an inherited genetic mutation.

Luxturna-is a liquid that is injected directly into the eye with a microscopic needle during a surgical procedure. The drug supplies a third gene -- a normal RPE65 gene -- to cells in the retina, a layer of tissue lining the back of the eye.-This third version of the gene does not remove or replace the two mutated genes causing the disease, which remain inside the cells. However, the normal gene delivered by the treatment is able to function within the retinal cells and correct vision problems.

In the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company. Risks of the treatment include cataracts, elevated eye pressure, retinal tears and holes and inflammation.

The company's offer of unusual payer models, including rebates and installment payments, will "help ensure patients' individual financial situation does not hinder access to treatment," da Silva said.

"New technologies such as gene and cell therapies hold out the potential to transform medicine," FDA Commissioner Dr. Scott Gottlieb-said in a statement announcing the August approval of Kymriah, considered to be the first gene therapy to be approved for the US market.

Kymriah is a leukemia treatment made by pharmaceutical giant Novartis. Similar to Luxturna, Kymriah is a one-time treatment, and its price tag is $475,000. However, Novartis said this price will not be charged to patients who do not respond within a month of treatment.

Mississippi Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 113876

Reported Deaths: 3238
CountyConfirmedDeaths
Hinds7894177
DeSoto693279
Harrison512983
Jackson450384
Rankin389486
Madison381293
Lee351479
Forrest300778
Jones289184
Washington256499
Lafayette248343
Lauderdale2437134
Lamar224238
Oktibbeha200854
Bolivar200477
Neshoba1842111
Lowndes178362
Panola169139
Leflore165887
Sunflower160949
Warren154355
Monroe148172
Pontotoc146119
Marshall141229
Lincoln138957
Pike138256
Copiah136936
Coahoma124936
Scott124929
Yazoo121733
Grenada121638
Simpson121249
Union117425
Tate116039
Leake114640
Holmes114460
Pearl River112959
Itawamba112225
Adams107343
Prentiss104819
Wayne100821
Alcorn98712
George97918
Covington97026
Marion94642
Tippah88922
Newton85627
Chickasaw84026
Tallahatchie84025
Winston83321
Hancock81628
Tishomingo80041
Attala79026
Clarke74351
Clay68421
Jasper67917
Walthall63827
Calhoun62212
Noxubee59617
Smith59116
Montgomery54323
Claiborne53716
Tunica52917
Yalobusha52614
Lawrence51214
Perry48723
Carroll48012
Greene47318
Stone46414
Humphreys42816
Amite42113
Quitman4196
Jefferson Davis40511
Webster37013
Wilkinson33720
Benton3335
Kemper32215
Sharkey28314
Jefferson27510
Franklin2403
Choctaw2056
Issaquena1074
Unassigned00

Alabama Coronavirus Cases

Confirmed Cases: 155915

Reported Deaths: 2674
CountyConfirmedDeaths
Jefferson22988375
Mobile16788315
Tuscaloosa10235140
Montgomery9978197
Madison922894
Shelby727463
Baldwin661569
Lee651765
Marshall437249
Calhoun422461
Etowah421450
Morgan407135
Houston371734
DeKalb336029
Elmore317353
St. Clair289142
Limestone279730
Walker275593
Talladega263635
Cullman239925
Lauderdale218042
Jackson212515
Franklin203231
Autauga203030
Colbert198731
Russell19283
Blount191125
Dallas186327
Chilton185832
Coffee173211
Escambia172230
Covington171429
Dale166551
Chambers134343
Clarke133617
Pike132713
Tallapoosa131387
Marion107129
Barbour10129
Butler100240
Marengo100222
Winston91913
Geneva8617
Lawrence83732
Pickens83618
Bibb82514
Randolph82016
Hale75830
Clay73612
Washington73412
Cherokee73114
Lowndes70428
Monroe64510
Henry6436
Bullock63917
Crenshaw60330
Perry5856
Fayette56913
Wilcox56412
Conecuh56013
Cleburne5518
Macon53020
Lamar4745
Sumter47221
Choctaw39012
Greene34216
Coosa2033
Out of AL00
Unassigned00
Tupelo
Overcast
54° wxIcon
Hi: 58° Lo: 52°
Feels Like: 54°
Columbus
Overcast
55° wxIcon
Hi: 62° Lo: 54°
Feels Like: 55°
Oxford
Overcast
50° wxIcon
Hi: 54° Lo: 47°
Feels Like: 50°
Starkville
Overcast
52° wxIcon
Hi: 58° Lo: 50°
Feels Like: 52°
WTVA Radar
WTVA Temperatures
WTVA Severe Weather